Stanley Specialty Pharmacy Compounding and Wellness Center, Charlotte, NC
Is Stanley Specialty Pharmacy Compounding and Wellness Center registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Stanley Specialty Pharmacy Compounding and Wellness Center hold a North Carolina pharmacy license?
State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
Has Stanley Specialty Pharmacy Compounding and Wellness Center had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Feb 8, 2022), 1 state referral letter (Feb 8, 2022) and 1 FMD-145 letter (Feb 8, 2022) for Stanley Specialty Pharmacy Compounding and Wellness Center. State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Stanley Specialty Pharmacy Compounding and Wellness Center
- Location
- Charlotte, NC
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Feb 8, 2022
- FDA Data Dashboard inspections
- 3 inspections: 1 OAI, 2 VAI; 3 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 8 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Stanley Specialty Pharmacy Compounding and Wellness Center, a 503A facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Feb 8, 2022 | State referral letter | State Referral Letter Issued 2/8/2022 | Not linked by FDA |
| Feb 8, 2022 | Warning letter close-out | Warning Letter Close Out Issued 02/08/2022 | Not linked by FDA |
| Feb 8, 2022 | FMD-145 letter | FMD-145 Letter Issued 02/08/2022 | Not linked by FDA |
| Oct 1, 2021 | Form 483 | 483 Issued 10/01/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Stanley Specialty Pharmacy Compounding and Wellness Center, Charlotte, NC (FEI number 3012184662), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Oct 1, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3012184662 | 1153610 |
| Aug 4, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012184662 | 1022804 |
| Jul 7, 2016 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs): Voluntary Action Indicated (VAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): No Action Indicated (NAI) | 3012184662 | 987173 |
Form 483s FDA has published for this site
- Oct 1, 2021: Form 483 to Stanley Specialty Pharmacy Compounding and Wellness Center, published Jan 28, 2022. fda.gov
- Sep 19, 2017: Form 483 to Stanley Specialty Pharmacy Compounding and Wellness Center, published Jan 17, 2024. fda.gov
- Aug 8, 2016: Form 483 to Stanley Specialty Pharmacy Compounding and Wellness Center, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 8 numbered observations in all, across 3 inspections ending Jul 7, 2016 to Oct 1, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Sep 20, 2021 to Oct 1, 2021: 1 observation
- Firm on the cover
- Stanley Specialty Pharmacy Compounding and Wellness Center, 3120 Latrobe Dr Ste 200, Charlotte, NC 28211-2185
- FEI number
- 3012184662
- Establishment type on the cover
- Producer of sterile and nonsterile drugs
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically,
1. Your firm failed to conduct media fills that closely simulate aseptic production operations that incorporate worse-case, most challenging, and stressful conditions. For example, your current media fill qualification procedure simulates a maximum fill of <Redacted B4> vials, and <Redacted B4> vials; however, your Lidocaine eye drops formulation (formula# 18491) is filled into 1-ml syringes in quantities between <Redacted B4> units over an extended duration.
Inspection Jul 31, 2017 to Aug 4, 2017: 3 observations
- Firm on the cover
- Stanley Specialty Pharmacy Compounding and Wellness Center, 3120 Latrobe Dr. Suite 200, Charlotte, NC 28211
- FEI number
- 3012184662
- Establishment type on the cover
- Producer of sterile and non-sterile drugs
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Environmental monitoring was not performed in your aseptic processing areas.
Specifically, <Redacted B4> samples collected within the ISO 8 <Redacted B4> and <Redacted B4> area, ISO 7 <Redacted B4> room, and <Redacted B4> IS0 5 laminar flow hoods, are <Redacted B4> collected on a <Redacted B4> basis after cleaning.
Observation 2
Disinfecting agents and cleaning pads or wipes used in the ISO 5 aseptic processing areas are not sterile.
Specifically, Your firm uses a non-sterile, non-sporocidal disinfectant <Redacted B4> with non-sterile wipes for all surfaces within the ISO classified areas, including in the ISO 5 laminar flow hoods where aseptic processes are conducted.
Observation 3
There is insufficient data to support the percentage of preservative used to ensure anti-microbial effectiveness in multi-dose stock solutions which are used to formulate finished product.
Add Continuation Page
Inspection Jun 6, 2016 to Jul 7, 2016: 4 observations
- Firm on the cover
- , 3120 Latrobe Dr Ste 200 Stanley Specialty Pharmacy Compounding and Wellness Center, ·-··
- FEI number
- 3012184662
- Establishment type on the cover
- Producer of Sterile Drugs Charlotte, NC 28211-2185
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
Your firm does not conduct environmental or personnel monitoring during or after sterile operations. Current procedures only require personnel monitoring (fingertip sampling) redacted (b)(4). Viable surface monitoring within the classified areas, including redacted (b)(4), is performed only redacted (b)(4), redacted (b)(4).
Your firm does not conduct environmental or personnel monitoring during or after sterile operations. Current procedures only require personnel monitoring (fingertip sampling) redacted (b)(4). Viable surface monitoring within the classified areas, including redacted (b)(4), is performed only redacted (b)(4), redacted (b)(4).
Your firm does not conduct environmental or personnel monitoring during or after sterile operations. Current procedures only require personnel monitoring (fingertip sampling) redacted (b)(4). Viable surface monitoring within the classified areas, including redacted (b)(4), is performed only redacted (b)(4), redacted (b)(4). Your firm does not conduct environmental or personnel monitoring during or after sterile operations. ...
Observation 2
·Protective apparel is not worn as necessary to protect drug products from contamination.
Specifically,
Employees performing manipulations in the production of drug products required to be sterile do not
wear sterile gowning. When fully gowned, operators have exposed skin on their neck, face, and forehead while working within the ISO 5 laminar air flow hoods.
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
Specifically, Your firm performs redacted (b)(4) of aseptic processes: redacted (b)(4). Media fills that have been conducted do not simulate actual production or include the most challenging conditions or manipulations to demonstrate that employed practices are reproducible and are not contributory to the microbiological contamination of the finished product.
Specifically, Your firm performs redacted (b)(4) of aseptic processes: redacted (b)(4). Media fills that have been conducted do not simulate actual production or include the most challenging conditions or manipulations to demonstrate that employed practices are reproducible and are not contributory to the microbiological contamination of the finished product.
Specifically, Your firm performs redacted (b)(4) of aseptic processes: redacted (b)(4). ...
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the areas to produce aseptic conditions. Specifically, and Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the areas to produce aseptic conditions. Specifically,
Your firm uses redacted (b)(4) as a sporicidal agent to clean and disinfect floors, ceilings, pass-thru boxes, and within the ISO 5 laminar air flow hood. There is no scientific data to support the concentration and contact time being used to achieve sporicidal disinfection. Your firm uses redacted (b)(4) as a sporicidal agent to clean and disinfect floors, ceilings, pass-thru boxes, and within the ISO 5 laminar air flow hood. There is no scientific data to support the concentration and contact time being used to achieve sporicidal disinfection. Your firm uses redacted (b)(4) as a sporicidal agent to clean and disinfect floors, ceilings, pass-thru boxes, and within the ISO 5 laminar air flow hood. There is no scientific data to support the concentration and contact time being used to achieve sporicidal disinfection. ...
State board of pharmacy records
State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.